首页> 外文期刊>Journal of viral hepatitis. >Long‐term outcome and recurrence of hepatitis B virus following liver transplantation from hepatitis B surface antigen‐positive donors in a Chinese population
【24h】

Long‐term outcome and recurrence of hepatitis B virus following liver transplantation from hepatitis B surface antigen‐positive donors in a Chinese population

机译:肝脏移植在中国人口中肝炎抗原阳性供体后肝炎病毒的长期结果和复发

获取原文
获取原文并翻译 | 示例
           

摘要

Summary Due to the severe shortage of the donor pool in China, a large number of patients are waiting for a suitable liver, or even worse lose the opportunity of transplantation. Reasonable use of hepatitis B surface antigen‐positive ( HB sAg‐positive) donors is one possible strategy to increase the donor pool but the long‐term outcome in a Chinese population is unknown. To evaluate the safety of using of HB sAg‐positive donor for liver transplantation, we set up a multicentric retrospective study from 1 January 2007 to 31 December 2012. A total of 8632 patients underwent liver transplantation during the period and 282 (2.97%) received a liver from a HB sAg‐positive donor. A total of 259 cases in both the case and control groups were matched. The incidence of postoperative liver dysfunction, early‐stage and long‐term complications and the 1‐, 3‐ and 5‐year patient survival (78.92% vs 85.65%, 60.41% vs 69.14%, 58.08% vs 69.14%, respectively) showed no difference between the two groups ( P value??0.05). However, the 1‐, 3‐ and 5‐year HBV recurrence for patients received the HB sAg‐positive donor was higher compared with controls (5.85% vs 1.97%, 11.63% vs 4.46%, 17.94% vs 4.46%, respectively, P value?=?0.016). Our results showed the use of HB sAg‐positive donors is feasible and postoperative antiviral therapy should be managed.
机译:总结由于中国捐赠池严重短缺,大量患者正在等待合适的肝脏,甚至更糟糕的失去移植机会。合理使用乙型肝炎表面抗原阳性(HB SAG阳性)捐助者是增加供体池的一种可能的策略,但中国人口的长期结果是未知的。为了评估使用HB SAG阳性供体进行肝移植的安全性,我们从2007年1月1日至2012年12月31日建立了多中心回顾性研究。总共有8632名患者在此期间接受肝移植,282名(2.97%)收到来自HB阳性供体的肝脏。案件和对照组共均为259例。术后肝功能障碍,早期和长期并发症的发病率和1-,3-和5年患者存活率(78.92%vs 85.65%,分别为58.08%vs 69.14%,显示出两组之间没有差异(P值?&?0.05)。然而,与对照组相比,患者的1-,3-和5年的HBV复发性较高,比对照(5.85%Vs 1.97%,11.63%,4.46%,分别为17.94%,P.价值?=?0.016)。我们的结果表明,使用HB阳性供体是可行的,并且应管理术后抗病毒治疗。

著录项

  • 来源
    《Journal of viral hepatitis.》 |2018年第12期|共6页
  • 作者单位

    Institute of Organ TransplantationHuazhong University of Science and TechnologyWuhan China;

    Institute of Organ TransplantationHuazhong University of Science and TechnologyWuhan China;

    Institute of Organ TransplantationHuazhong University of Science and TechnologyWuhan China;

    Institute of Organ TransplantationHuazhong University of Science and TechnologyWuhan China;

    Institute of Organ TransplantationHuazhong University of Science and TechnologyWuhan China;

    Institute of Organ TransplantationHuazhong University of Science and TechnologyWuhan China;

    Institute of Organ TransplantationHuazhong University of Science and TechnologyWuhan China;

    Institute of Organ TransplantationHuazhong University of Science and TechnologyWuhan China;

    Institute of Organ TransplantationHuazhong University of Science and TechnologyWuhan China;

    Institute of Organ TransplantationHuazhong University of Science and TechnologyWuhan China;

    Institute of Organ TransplantationHuazhong University of Science and TechnologyWuhan China;

  • 收录信息
  • 原文格式 PDF
  • 正文语种 eng
  • 中图分类 传染病;
  • 关键词

    anti‐ HBV therapy; hepatitis B surface antigen‐positive donor; liver transplantation;

    机译:抗HBV疗法;乙型肝炎表面抗原阳性供体;肝移植;

相似文献

  • 外文文献
  • 中文文献
  • 专利
获取原文

客服邮箱:kefu@zhangqiaokeyan.com

京公网安备:11010802029741号 ICP备案号:京ICP备15016152号-6 六维联合信息科技 (北京) 有限公司©版权所有
  • 客服微信

  • 服务号